Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CC-220 + rifampin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CC-220 + rifampin is a combination of iberdomide (CC-220), a small molecule cereblon E3 ligase modulator, and rifampin, a rifamycin class antibiotic. Iberdomide acts by binding and modulating cereblon, the substrate receptor for the CRL4^CRBN^ E3 ubiquitin ligase complex, leading to degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), producing immunomodulatory and antitumor effects. It is primarily in clinical development for relapsed/refractory multiple myeloma (MM) and systemic lupus erythematosus (SLE)[1][3][5][7]. Rifampin, included in this combination, is not a conventional component of iberdomide therapy; it is a potent inducer of drug-metabolizing enzymes (notably CYP3A4), known to significantly reduce the systemic exposure of many orally administered drugs including immunomodulatory agents.
- Brand names
- iberdomide
- Other names
- CC-220 + rifampin
02
Targets
RNAP (Bacterial dna-dependent RNA polymerase)IKZF1 (Ikaros family zinc finger protein 1)CYP3A4 (Cytochrome P450 3A4)CRBN (Cereblon)IKZF3 (Zinc finger protein Aiolos)
Beyond the preview
Go deeper on CC-220 + rifampin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CC-220 + rifampin.